Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo
Investors sentiment increased to 0.62 in 2019 Q1. Its up 0.01, from 0.61 in 2018Q4. It increased, as 11 investors sold Applied Genetic Technologies Corporation shares while 15 reduced holdings. 7 funds opened positions while 9 raised stakes. 5.75 million shares or 7.80% less from 6.24 million shares in 2018Q4 were reported.
Meeder Asset Management holds 641 shares. 7,900 are held by Tower Research Ltd Llc (Trc). 82,686 are held by Geode Mngmt Ltd Liability Corporation. Moreover, 683 Capital Mgmt Lc has 0.08% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 200,000 shares. Deutsche Comml Bank Ag owns 400 shares. Jacobs Levy Equity Mgmt Incorporated invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). 600,231 were reported by Vanguard Group Inc Inc. Steinberg Asset accumulated 177,154 shares. Commercial Bank Of America De invested 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Spark Invest Ltd Liability Corp invested in 50,700 shares. Price T Rowe Assoc Md has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Sei Investments reported 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Jpmorgan Chase Comm stated it has 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Dafna Management Limited Liability Company holds 359,190 shares. Barclays Pcl owns 84 shares for 0% of their portfolio.

Analysts expect Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report $-0.46 EPS on September, 9.They anticipate $0.09 EPS change or 24.32 % from last quarter’s $-0.37 EPS. After having $0.63 EPS previously, Applied Genetic Technologies Corporation’s analysts see -173.02 % EPS growth. The stock decreased 0.52% or $0.02 during the last trading session, reaching $3.83. About 95,974 shares traded or 75.39% up from the average. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 5.28% since August 10, 2018 and is downtrending. It has underperformed by 5.28% the S&P500.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $69.60 million. The company’s lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has a 40.74 P/E ratio. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link